Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC targets weight loss marketer

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission charges a California business with falsely claiming its weight-loss pills cause users to lose weight without dieting or exercise, the agency says Feb. 8. The complaint, filed in the U.S. District Court for the Northern District of California, charges defendants Medlab, Pinnacle Holdings and Metabolic Research Associates and their principal, L. Scott Holmes, with making false and unsubstantiated claims in newspaper supplements for products Zyladex Plus, Questral AC, Questral AC Fat Killer Plus, Rapid Loss 245 and Rapid Loss Rx. The claims included "lose up to 15 pounds a week" and "not even starvation can slim you down and firm you up this fast." FTC says it seeks to "permanently bar the defendants from further violations" as well refunds for affected consumers...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101369

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel